HC Wainwright & Co. Reiterates Buy on InflaRx, Maintains $8 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Edward White has reiterated a Buy rating on InflaRx (NASDAQ:IFRX), maintaining an $8 price target.

May 09, 2024 | 10:52 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. reaffirms a Buy rating on InflaRx with an $8 price target, as per analyst Edward White.
The reiteration of a Buy rating and maintenance of an $8 price target by a reputable analyst like Edward White could instill confidence in investors and potentially lead to a positive short-term impact on InflaRx's stock price. The endorsement reflects a strong belief in the company's value and prospects.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100